American urologists express increased interest in focused ultrasound

Recent comments by executives of EDAP TMS and US HIFU indicate that interest in focused ultrasound treatment for prostate cancer is increasing among members of the American Urological Association. Marc Oczachowski, Chief Executive Officer of EDAP TMS, said that the company “experienced record attendance and exceptional enthusiasm from U.S. urologists” at its exhibit booth at the AUA meeting, which was held May 19–23, 2012 in Atlanta. He noted that “awareness levels are building” as the company prepares for to submit its Ablatherm-HIFU filing to the US FDA later this year.

Recent comments by executives of EDAP TMS and US HIFU indicate that interest in focused ultrasound treatment for prostate cancer is increasing among members of the American Urological Association. Marc Oczachowski, Chief Executive Officer of EDAP TMS, said that the company “experienced record attendance and exceptional enthusiasm from U.S. urologists” at its exhibit booth at the AUA meeting, which was held May 19–23, 2012 in Atlanta. He noted that “awareness levels are building” as the company prepares for to submit its Ablatherm-HIFU filing to the US FDA later this year. READ PRESS RELEASE

Mike Klein, US HIFU Chief Executive Officer said, “We have an unprecedented number of meetings scheduled at AUA.” He added that the company, which is conducting US clinical trials of its Sonoblate system, was “actively seeking insight from urologists to guide the development of HIFU technologies to further enhance the safety and efficacy and identify areas of interest to focus studies and clinical trials for a wide range of applications.” READ PRESS RELEASE